What is the mechanism of action of ritexitinib tosylate capsules?

Ritlecitinib is an oral small molecule drug that is a JAK3 inhibitor. It is mainly used to treat diseases caused by immune system abnormalities, especially severe alopecia areata . Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, causing hair loss. As a new JAK3 inhibitor, ritexitinib's unique mechanism of action makes it have significant clinical value in the treatment of immune-mediated diseases such as alopecia areata.

JAK (Janus kinase) is an important intracellular tyrosine kinase that participates in multiple cytokine receptor signaling pathways. The JAK kinase family includes JAK1, JAK2, JAK3 and TYK2, among which JAK3 is mainly involved in signal transduction related to the immune system. In particular, JAK3 plays a crucial role in the function of immune cells such as T cells and natural killer cells (NK cells). JAK3 activates downstream signaling pathways by binding to cytokine receptors, promoting cell proliferation, differentiation and immune response.

In a healthy immune system, JAK3 activity is strictly regulated to ensure normal immune response. However, in some autoimmune diseases, such as alopecia areata, the immune system goes awry and mistakenly attacks normal tissues of the body, including hair follicles. The immune system of people with alopecia areata produces an excessive immune response, leading to inflammation of the hair follicles and ultimately hair loss. JAK3 plays a key role in this process.

Ritexitinib blocks the activity of JAK3 kinase by targetingJAK3, thereby inhibiting the immune system's attack on hair follicles. It binds to the ATP binding site of JAK3 and inhibits its tyrosine kinase activity, thereby reducing immune cell activity and immune response. This mechanism can effectively reduce inflammation caused by immune response, thereby inhibiting the destruction of hair follicles and promoting hair regeneration. Compared with traditional immunosuppressants, the advantage of ritexitinib is that it has strong targeting and can specifically inhibit the activity of JAK3 without directly interfering with the functions of other JAK family members, so it has relatively few side effects.

Reference materials:https://www.litfulo.com/